Innovent to Present IBI363 and IBI343 Data at ESMO Events

Innovent Biologics, Inc. (HKEX: 01801), a renowned biopharmaceutical company, has announced that it will present clinical data on its groundbreaking PD-1/IL-2 bispecific antibody fusion protein (IBI363) and its novel anti-Claudin18.2 ADC (IBI343) at upcoming medical conferences in June 2024. These presentations will take place at the ESMO Virtual Plenary and the ESMO Gastrointestinal Cancers Congress (ESMO GI) 2024.

The ESMO Virtual Plenary, scheduled for June 13-14, 2024, will feature an oral presentation on IBI363, a first-in-class PD-1/IL-2 bispecific antibody fusion protein. This presentation, titled "First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced solid tumors: First-in-human phase I study," will be delivered by Professor Xueli Bai from Zhejiang University School of Medicine. The presentation will occur on June 13 from 18:30 to 19:30 CEST and on June 14 from 13:00 to 14:10 CEST.

Subsequently, the ESMO Gastrointestinal Cancers Congress will take place from June 26-29, 2024, in Munich, Germany. During this congress, Innovent will present data on IBI343, an anti-Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC). The oral presentation, titled "Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients with solid tumors and gastric/gastro-esophageal junction adenocarcinoma: A phase 1 study," will be delivered by Jenny Liu from St Vincent's Hospital Sydney. This presentation is scheduled for June 29 from 08:45 to 10:00 CEST.

Dr. Hui Zhou, Senior Vice President of Innovent, emphasized the importance of these presentations, stating that the clinical data underscore the potential efficacy and safety of Innovent's innovative bispecific antibodies and ADC molecules. He highlighted that Innovent's advanced antibody-based platform, unique ADC technology, and profound scientific expertise are instrumental in developing a new generation of innovative therapies. The goal is to address unmet medical needs and bridge treatment gaps for cancer patients globally.

Founded in 2011, Innovent Biologics is a leading biopharmaceutical company dedicated to creating high-quality, affordable biologics. The company's mission is to discover, develop, manufacture, and commercialize innovative therapies for some of the most challenging diseases, including cancer, cardiovascular and metabolic disorders, autoimmune diseases, and ophthalmic conditions. Innovent currently markets 10 products, has three new drug applications under review by the NMPA, and is conducting five Phase III or pivotal clinical trials. Additionally, the company has 18 more molecules in early clinical stages. Innovent collaborates with over 30 global healthcare leaders, such as Eli Lilly, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center.

Innovent's guiding principle is "Start with Integrity, Succeed through Action." The company strives to uphold the highest industry standards and works collaboratively to advance the biopharmaceutical field, making top-tier pharmaceutical drugs accessible worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!